FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379600583> ?p ?o ?g. }

• W4379600583 endingPage "949" @default.
• W4379600583 startingPage "941" @default.
• W4379600583 abstract "Camostat inhibits severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in vitro. We studied the safety and efficacy of camostat in ACTIV-2/A5401, a phase 2/3 platform trial of therapeutics for COVID-19 in nonhospitalized adults.We conducted a phase 2 study in adults with mild-to-moderate COVID-19 randomized to oral camostat for 7 days or a pooled placebo arm. Primary outcomes were time to improvement in COVID-19 symptoms through day 28, proportion of participants with SARS-CoV-2 RNA below the lower limit of quantification (LLoQ) from nasopharyngeal swabs through day 14, and grade ≥3 treatment-emergent adverse events (TEAEs) through day 28.Of 216 participants (109 randomized to camostat, 107 to placebo) who initiated study intervention, 45% reported ≤5 days of symptoms at study entry and 26% met the protocol definition of higher risk of progression to severe COVID-19. Median age was 37 years. Median time to symptom improvement was 9 days in both arms (P = .99). There were no significant differences in the proportion of participants with SARS-CoV-2 RNA <LLoQ on days 3, 7, and 14. Through day 28, 6 (5.6%) participants in the camostat arm and 5 (4.7%) in the placebo arm were hospitalized; 1 participant in the camostat arm subsequently died. Grade ≥3 TEAEs occurred in 10.1% of camostat versus 6.5% of placebo participants (P = .35).In a phase 2 study of nonhospitalized adults with mild-to-moderate COVID-19, oral camostat did not accelerate viral clearance or time to symptom improvement, or reduce hospitalizations or deaths. Clinical Trials Registration. ClinicalTrials.gov identifier: NCT04518410." @default.
• W4379600583 created "2023-06-08" @default.
• W4379600583 creator A5010273640 @default.
• W4379600583 creator A5010897684 @default.
• W4379600583 creator A5012543541 @default.
• W4379600583 creator A5012767113 @default.
• W4379600583 creator A5012906901 @default.
• W4379600583 creator A5017137912 @default.
• W4379600583 creator A5019165039 @default.
• W4379600583 creator A5024029270 @default.
• W4379600583 creator A5024560316 @default.
• W4379600583 creator A5027304381 @default.
• W4379600583 creator A5036716419 @default.
• W4379600583 creator A5038377747 @default.
• W4379600583 creator A5053117575 @default.
• W4379600583 creator A5059572608 @default.
• W4379600583 creator A5060710888 @default.
• W4379600583 creator A5063779717 @default.
• W4379600583 creator A5082238950 @default.
• W4379600583 creator A5083949967 @default.
• W4379600583 creator A5084353681 @default.
• W4379600583 creator A5086686047 @default.
• W4379600583 date "2023-06-05" @default.
• W4379600583 modified "2023-10-11" @default.
• W4379600583 title "One Week of Oral Camostat Versus Placebo in Nonhospitalized Adults With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19): A Randomized Controlled Phase 2 Trial" @default.
• W4379600583 cites W2081719521 @default.
• W4379600583 cites W3009577418 @default.
• W4379600583 cites W3009912996 @default.
• W4379600583 cites W3104727101 @default.
• W4379600583 cites W3115009914 @default.
• W4379600583 cites W3133812656 @default.
• W4379600583 cites W3156990363 @default.
• W4379600583 cites W3173514762 @default.
• W4379600583 cites W3173686570 @default.
• W4379600583 cites W3193911193 @default.
• W4379600583 cites W3205193484 @default.
• W4379600583 cites W4200051875 @default.
• W4379600583 cites W4200206478 @default.
• W4379600583 cites W4200272387 @default.
• W4379600583 cites W4210643204 @default.
• W4379600583 cites W4210665241 @default.
• W4379600583 cites W4210778472 @default.
• W4379600583 cites W4220886953 @default.
• W4379600583 cites W4221055373 @default.
• W4379600583 cites W4226236384 @default.
• W4379600583 cites W4284688873 @default.
• W4379600583 cites W4286009139 @default.
• W4379600583 cites W4292291627 @default.
• W4379600583 cites W4297249038 @default.
• W4379600583 cites W4307910864 @default.
• W4379600583 cites W4311480784 @default.
• W4379600583 cites W4313500418 @default.
• W4379600583 doi "https://doi.org/10.1093/cid/ciad342" @default.
• W4379600583 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37279602" @default.
• W4379600583 hasPublicationYear "2023" @default.
• W4379600583 type Work @default.
• W4379600583 citedByCount "1" @default.
• W4379600583 countsByYear W43796005832023 @default.
• W4379600583 crossrefType "journal-article" @default.
• W4379600583 hasAuthorship W4379600583A5010273640 @default.
• W4379600583 hasAuthorship W4379600583A5010897684 @default.
• W4379600583 hasAuthorship W4379600583A5012543541 @default.
• W4379600583 hasAuthorship W4379600583A5012767113 @default.
• W4379600583 hasAuthorship W4379600583A5012906901 @default.
• W4379600583 hasAuthorship W4379600583A5017137912 @default.
• W4379600583 hasAuthorship W4379600583A5019165039 @default.
• W4379600583 hasAuthorship W4379600583A5024029270 @default.
• W4379600583 hasAuthorship W4379600583A5024560316 @default.
• W4379600583 hasAuthorship W4379600583A5027304381 @default.
• W4379600583 hasAuthorship W4379600583A5036716419 @default.
• W4379600583 hasAuthorship W4379600583A5038377747 @default.
• W4379600583 hasAuthorship W4379600583A5053117575 @default.
• W4379600583 hasAuthorship W4379600583A5059572608 @default.
• W4379600583 hasAuthorship W4379600583A5060710888 @default.
• W4379600583 hasAuthorship W4379600583A5063779717 @default.
• W4379600583 hasAuthorship W4379600583A5082238950 @default.
• W4379600583 hasAuthorship W4379600583A5083949967 @default.
• W4379600583 hasAuthorship W4379600583A5084353681 @default.
• W4379600583 hasAuthorship W4379600583A5086686047 @default.
• W4379600583 hasConcept C126322002 @default.
• W4379600583 hasConcept C142724271 @default.
• W4379600583 hasConcept C168563851 @default.
• W4379600583 hasConcept C197934379 @default.
• W4379600583 hasConcept C204787440 @default.
• W4379600583 hasConcept C27081682 @default.
• W4379600583 hasConcept C71924100 @default.
• W4379600583 hasConcept C90924648 @default.
• W4379600583 hasConceptScore W4379600583C126322002 @default.
• W4379600583 hasConceptScore W4379600583C142724271 @default.
• W4379600583 hasConceptScore W4379600583C168563851 @default.
• W4379600583 hasConceptScore W4379600583C197934379 @default.
• W4379600583 hasConceptScore W4379600583C204787440 @default.
• W4379600583 hasConceptScore W4379600583C27081682 @default.
• W4379600583 hasConceptScore W4379600583C71924100 @default.
• W4379600583 hasConceptScore W4379600583C90924648 @default.
• W4379600583 hasFunder F4320332161 @default.
• W4379600583 hasFunder F4320337355 @default.
• W4379600583 hasIssue "7" @default.

• next